Featured Content: To Display at Bottom of Article

Data from the T-DXd monotherapy arm of the phase 3 DESTINY-Breast09 trial will remain blinded until the final PFS analysis.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

A 5-year follow-up of the phase 3 EMPOWER-Lung 1 showed the greatest survival benefits in patients with NSCLC who have a PD-L1 expression of 90% or more.